JP2001501471A - 血管新生の阻害のための遺伝子治療 - Google Patents
血管新生の阻害のための遺伝子治療Info
- Publication number
- JP2001501471A JP2001501471A JP10515840A JP51584098A JP2001501471A JP 2001501471 A JP2001501471 A JP 2001501471A JP 10515840 A JP10515840 A JP 10515840A JP 51584098 A JP51584098 A JP 51584098A JP 2001501471 A JP2001501471 A JP 2001501471A
- Authority
- JP
- Japan
- Prior art keywords
- vegf
- cells
- tumor
- recombinant
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000033115 angiogenesis Effects 0.000 title claims abstract description 31
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 16
- 238000001415 gene therapy Methods 0.000 title abstract description 29
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims abstract description 82
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 79
- 238000000034 method Methods 0.000 claims abstract description 64
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 claims abstract description 31
- 230000014509 gene expression Effects 0.000 claims abstract description 31
- 210000003556 vascular endothelial cell Anatomy 0.000 claims abstract description 22
- 230000004614 tumor growth Effects 0.000 claims abstract description 17
- 230000005747 tumor angiogenesis Effects 0.000 claims abstract description 15
- 102000005962 receptors Human genes 0.000 claims abstract description 14
- 108020003175 receptors Proteins 0.000 claims abstract description 14
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 claims abstract description 10
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 claims abstract description 10
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims abstract 16
- 210000004027 cell Anatomy 0.000 claims description 126
- 239000013598 vector Substances 0.000 claims description 52
- 108020004414 DNA Proteins 0.000 claims description 44
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 claims description 30
- 241000700605 Viruses Species 0.000 claims description 30
- 241000701161 unidentified adenovirus Species 0.000 claims description 26
- 239000012634 fragment Substances 0.000 claims description 22
- 241000699670 Mus sp. Species 0.000 claims description 17
- 210000004881 tumor cell Anatomy 0.000 claims description 14
- 108020004511 Recombinant DNA Proteins 0.000 claims description 11
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 8
- 239000000539 dimer Substances 0.000 claims description 8
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
- 210000001789 adipocyte Anatomy 0.000 claims description 4
- 102000050995 human FLT1 Human genes 0.000 claims description 4
- 210000000663 muscle cell Anatomy 0.000 claims description 4
- 108091008605 VEGF receptors Proteins 0.000 claims description 3
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 108091008601 sVEGFR Proteins 0.000 claims description 2
- 239000013600 plasmid vector Substances 0.000 claims 5
- 230000001276 controlling effect Effects 0.000 claims 1
- 210000000448 cultured tumor cell Anatomy 0.000 claims 1
- 210000004882 non-tumor cell Anatomy 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 abstract description 16
- 230000027455 binding Effects 0.000 abstract description 16
- 230000012010 growth Effects 0.000 abstract description 15
- 206010027476 Metastases Diseases 0.000 abstract description 14
- 230000015572 biosynthetic process Effects 0.000 abstract description 12
- 230000009401 metastasis Effects 0.000 abstract description 12
- 239000002773 nucleotide Substances 0.000 abstract description 12
- 125000003729 nucleotide group Chemical group 0.000 abstract description 12
- 108020004999 messenger RNA Proteins 0.000 abstract description 10
- 230000001225 therapeutic effect Effects 0.000 abstract description 6
- 206010061218 Inflammation Diseases 0.000 abstract description 4
- 201000004681 Psoriasis Diseases 0.000 abstract description 4
- 201000011066 hemangioma Diseases 0.000 abstract description 4
- 239000000833 heterodimer Substances 0.000 abstract description 4
- 230000004054 inflammatory process Effects 0.000 abstract description 4
- 208000002780 macular degeneration Diseases 0.000 abstract description 4
- 230000002297 mitogenic effect Effects 0.000 abstract description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract description 4
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract description 3
- 230000002491 angiogenic effect Effects 0.000 abstract description 3
- 108091008598 receptor tyrosine kinases Proteins 0.000 abstract description 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 abstract description 2
- 230000004068 intracellular signaling Effects 0.000 abstract 1
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 70
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 70
- 108090000623 proteins and genes Proteins 0.000 description 44
- 239000013612 plasmid Substances 0.000 description 31
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 20
- 125000003275 alpha amino acid group Chemical group 0.000 description 17
- 239000002299 complementary DNA Substances 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 238000001727 in vivo Methods 0.000 description 12
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 11
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 11
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 11
- 150000001413 amino acids Chemical class 0.000 description 11
- 230000003612 virological effect Effects 0.000 description 11
- 239000013604 expression vector Substances 0.000 description 10
- 238000001890 transfection Methods 0.000 description 10
- 238000012546 transfer Methods 0.000 description 10
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 9
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 description 9
- 102100038232 Vascular endothelial growth factor C Human genes 0.000 description 9
- 238000012384 transportation and delivery Methods 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 8
- 238000010276 construction Methods 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 102000009521 Vascular Endothelial Growth Factor B Human genes 0.000 description 7
- 108010073925 Vascular Endothelial Growth Factor B Proteins 0.000 description 7
- 208000005017 glioblastoma Diseases 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 210000004379 membrane Anatomy 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 6
- 108091000080 Phosphotransferase Proteins 0.000 description 6
- 108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 description 6
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 6
- 102100038234 Vascular endothelial growth factor D Human genes 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 102000020233 phosphotransferase Human genes 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 5
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 5
- 108700020796 Oncogene Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 108020005202 Viral DNA Proteins 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 229960002897 heparin Drugs 0.000 description 5
- 229920000669 heparin Polymers 0.000 description 5
- 102000058223 human VEGFA Human genes 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 238000010253 intravenous injection Methods 0.000 description 5
- 229940065638 intron a Drugs 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000001394 metastastic effect Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 208000032612 Glial tumor Diseases 0.000 description 4
- 206010018338 Glioma Diseases 0.000 description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 4
- 102000001253 Protein Kinase Human genes 0.000 description 4
- 102000016663 Vascular Endothelial Growth Factor Receptor-3 Human genes 0.000 description 4
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 210000002889 endothelial cell Anatomy 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 238000011580 nude mouse model Methods 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 108060006633 protein kinase Proteins 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 3
- 201000008808 Fibrosarcoma Diseases 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 108700019146 Transgenes Proteins 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 208000009956 adenocarcinoma Diseases 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 239000000710 homodimer Substances 0.000 description 3
- 230000006801 homologous recombination Effects 0.000 description 3
- 238000002744 homologous recombination Methods 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 239000003226 mitogen Substances 0.000 description 3
- 230000011278 mitosis Effects 0.000 description 3
- 239000002777 nucleoside Substances 0.000 description 3
- 150000003833 nucleoside derivatives Chemical class 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- 208000003120 Angiofibroma Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 241000255925 Diptera Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 101001001487 Homo sapiens Phosphatidylinositol-glycan biosynthesis class F protein Proteins 0.000 description 2
- 101000742579 Homo sapiens Vascular endothelial growth factor B Proteins 0.000 description 2
- 241001477931 Mythimna unipuncta Species 0.000 description 2
- 108091061960 Naked DNA Proteins 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- -1 VEGF-RTMI Proteins 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000002716 delivery method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037765 diseases and disorders Diseases 0.000 description 2
- 230000003090 exacerbative effect Effects 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 102000056450 human PIGF Human genes 0.000 description 2
- 102000058241 human VEGFB Human genes 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 2
- 229920000656 polylysine Polymers 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000033458 reproduction Effects 0.000 description 2
- 102220240796 rs553605556 Human genes 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000003153 stable transfection Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000003146 transient transfection Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 208000010370 Adenoviridae Infections Diseases 0.000 description 1
- 206010060931 Adenovirus infection Diseases 0.000 description 1
- 108010002913 Asialoglycoproteins Proteins 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000009458 Carcinoma in Situ Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 1
- 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 241000192700 Cyanobacteria Species 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 108091060211 Expressed sequence tag Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 101000742599 Homo sapiens Vascular endothelial growth factor D Proteins 0.000 description 1
- 241000598171 Human adenovirus sp. Species 0.000 description 1
- 239000012741 Laemmli sample buffer Substances 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000785747 Mavirus Species 0.000 description 1
- 208000007054 Medullary Carcinoma Diseases 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 208000034038 Pathologic Neovascularization Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 101710098940 Pro-epidermal growth factor Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 206010067868 Skin mass Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 108700029229 Transcriptional Regulatory Elements Proteins 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 206010050283 Tumour ulceration Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 102000016548 Vascular Endothelial Growth Factor Receptor-1 Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000011589 adenoviridae infectious disease Diseases 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 108091007497 betacoronavirus-specific marker domains Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 201000007455 central nervous system cancer Diseases 0.000 description 1
- 208000025997 central nervous system neoplasm Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 210000004714 cranial suture Anatomy 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 208000030381 cutaneous melanoma Diseases 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 235000021186 dishes Nutrition 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000011013 endotoxin removal Methods 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 201000004933 in situ carcinoma Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 208000003849 large cell carcinoma Diseases 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 1
- 210000003757 neuroblast Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 201000002575 ocular melanoma Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 201000005825 prostate adenocarcinoma Diseases 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 208000014212 sarcomatoid carcinoma Diseases 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 201000003708 skin melanoma Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 201000007423 tubular adenocarcinoma Diseases 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 108010002164 tyrosine receptor Proteins 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 230000006459 vascular development Effects 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 108010015889 zeta receptor Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2664196P | 1996-09-24 | 1996-09-24 | |
| US60/026,641 | 1996-09-24 | ||
| PCT/US1997/017044 WO1998013071A1 (en) | 1996-09-24 | 1997-09-24 | Gene therapy for inhibition of angiogenesis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2001501471A true JP2001501471A (ja) | 2001-02-06 |
| JP2001501471A5 JP2001501471A5 (https=) | 2005-05-12 |
Family
ID=21833003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP10515840A Pending JP2001501471A (ja) | 1996-09-24 | 1997-09-24 | 血管新生の阻害のための遺伝子治療 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6375929B1 (https=) |
| EP (1) | EP0928203B1 (https=) |
| JP (1) | JP2001501471A (https=) |
| AT (1) | ATE343400T1 (https=) |
| AU (1) | AU738806B2 (https=) |
| CA (1) | CA2266419A1 (https=) |
| DE (1) | DE69736860T2 (https=) |
| ES (1) | ES2274549T3 (https=) |
| WO (1) | WO1998013071A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013516169A (ja) * | 2009-12-31 | 2013-05-13 | インダストリー−ユニバーシティー コーポレーション ファウンデーション ハンヤン ユニバーシティー | 抗血管新生活性を有する組換えアデノウイルス |
Families Citing this family (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9723780D0 (en) * | 1997-11-12 | 1998-01-07 | Univ Manchester | Regulation of ocular angiogenesis |
| CA2348835A1 (en) | 1998-10-28 | 2000-05-04 | Cornell Research Foundation, Inc. | Methods for regulating angiogenesis and vascular integrity using trk receptor ligands |
| US7393823B1 (en) | 1999-01-20 | 2008-07-01 | Oregon Health And Science University | HER-2 binding antagonists |
| US7396810B1 (en) * | 2000-08-14 | 2008-07-08 | Oregon Health Sciences University | Compositions and methods for treating cancer by modulating HER-2 and EGF receptors |
| US7625859B1 (en) | 2000-02-16 | 2009-12-01 | Oregon Health & Science University | HER-2 binding antagonists |
| AU3755900A (en) * | 1999-03-15 | 2000-10-04 | Chiron Corporation | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
| US6943153B1 (en) | 1999-03-15 | 2005-09-13 | The Regents Of The University Of California | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
| US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US7303746B2 (en) | 1999-06-08 | 2007-12-04 | Regeneron Pharmaceuticals, Inc. | Methods of treating eye disorders with modified chimeric polypeptides |
| US6833349B2 (en) * | 1999-06-08 | 2004-12-21 | Regeneron Pharmaceuticals, Inc. | Methods of treating inflammatory skin diseases |
| US7306799B2 (en) | 1999-06-08 | 2007-12-11 | Regeneron Pharmaceuticals, Inc. | Use of VEGF inhibitors for treatment of eye disorders |
| US7653769B2 (en) * | 2006-12-14 | 2010-01-26 | International Business Machines Corporation | Management of devices connected to infiniband ports |
| US6821775B1 (en) * | 2000-02-11 | 2004-11-23 | Genvec, Inc. | Viral vector encoding pigment epithelium-derived factor |
| AUPQ592100A0 (en) * | 2000-02-29 | 2000-03-23 | Council Of The Queensland Institute Of Medical Research, The | A method of treatment and prophylaxis |
| HUP0300810A2 (hu) | 2000-07-20 | 2003-08-28 | M.G.V.S. Ltd. | Mesterséges értranszplantátum, valamint ennek létrehozása és alkalmazása |
| US7175658B1 (en) | 2000-07-20 | 2007-02-13 | Multi-Gene Vascular Systems Ltd. | Artificial vascular grafts, their construction and use |
| WO2002024234A2 (en) * | 2000-09-20 | 2002-03-28 | The Regents Of The University Of California | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
| GB0109781D0 (en) * | 2001-04-20 | 2001-06-13 | Oxford Biomedica Ltd | Vector system |
| WO2003062788A2 (en) * | 2002-01-17 | 2003-07-31 | Genetix Pharamaceuticals, Inc. | Method for inhibiting angiogenesis |
| AU2003215163A1 (en) * | 2002-02-12 | 2003-09-04 | Vanderbilt University | Inhibition of vegf receptor signaling reverses tumor resistance to radiotherapy |
| US20060234969A1 (en) * | 2003-03-07 | 2006-10-19 | Anges Mg, Inc. | Compositions and methods for inhibiting inflammation of vessel walls and formation of neointimal hyperplasia |
| JP2007528355A (ja) * | 2003-03-07 | 2007-10-11 | アンジェスＭｇ株式会社 | 血管壁の炎症および新生内膜過形成を阻害する組成物および方法 |
| US20050239088A1 (en) * | 2003-05-16 | 2005-10-27 | Shepard H M | Intron fusion proteins, and methods of identifying and using same |
| PT1638591E (pt) | 2003-05-29 | 2013-05-22 | Univ Manchester | Agonistas de slrp de classe iii para a redução da formação de vasos sanguíneos |
| US7186699B2 (en) | 2003-06-03 | 2007-03-06 | Cell Genesys, Inc. | Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes |
| US7399612B2 (en) | 2003-06-30 | 2008-07-15 | Regeneron Pharmaceuticals, Inc. | VEGF-binding fusion proteins and nucleic acids encoding the same |
| NZ592039A (en) | 2003-08-27 | 2013-03-28 | Ophthotech Corp | Combination therapy for the treatment of ocular neovascular disorders |
| WO2005087808A2 (en) | 2004-03-05 | 2005-09-22 | Ludwig Institute For Cancer Research | Growth factor binding constructs materials and methods |
| JP2008506366A (ja) * | 2004-05-14 | 2008-03-06 | レセプター バイオロジックス インコーポレイテッド | 細胞表面受容体アイソフォームならびにその同定および使用方法 |
| US20070224194A1 (en) * | 2004-05-20 | 2007-09-27 | Ludwig Institute For Cancer Research | Methods for Inhibiting Angiogenesis and/or Lymphangiogenesis |
| CA2576030A1 (en) * | 2004-08-09 | 2006-02-23 | Alios Biopharma Inc. | Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same |
| US7597884B2 (en) * | 2004-08-09 | 2009-10-06 | Alios Biopharma, Inc. | Hyperglycosylated polypeptide variants and methods of use |
| US20060047153A1 (en) * | 2004-09-02 | 2006-03-02 | Wonders Alan G | Optimized liquid-phase oxidation |
| US7692036B2 (en) | 2004-11-29 | 2010-04-06 | Eastman Chemical Company | Optimized liquid-phase oxidation |
| US7741515B2 (en) * | 2004-09-02 | 2010-06-22 | Eastman Chemical Company | Optimized liquid-phase oxidation |
| US7589231B2 (en) * | 2004-09-02 | 2009-09-15 | Eastman Chemical Company | Optimized liquid-phase oxidation |
| US7683210B2 (en) * | 2004-09-02 | 2010-03-23 | Eastman Chemical Company | Optimized liquid-phase oxidation |
| US7381836B2 (en) * | 2004-09-02 | 2008-06-03 | Eastman Chemical Company | Optimized liquid-phase oxidation |
| US7482482B2 (en) | 2004-09-02 | 2009-01-27 | Eastman Chemical Company | Optimized liquid-phase oxidation |
| US7399882B2 (en) * | 2004-09-02 | 2008-07-15 | Eastman Chemical Company | Optimized liquid-phase oxidation |
| US7586000B2 (en) * | 2004-09-02 | 2009-09-08 | Eastman Chemical Company | Optimized liquid-phase oxidation |
| US7361784B2 (en) * | 2004-09-02 | 2008-04-22 | Eastman Chemical Company | Optimized liquid-phase oxidation |
| US7608733B2 (en) * | 2004-09-02 | 2009-10-27 | Eastman Chemical Company | Optimized liquid-phase oxidation |
| US7504535B2 (en) * | 2004-09-02 | 2009-03-17 | Eastman Chemical Company | Optimized liquid-phase oxidation |
| US7910769B2 (en) * | 2004-09-02 | 2011-03-22 | Eastman Chemical Company | Optimized liquid-phase oxidation |
| US7371894B2 (en) * | 2004-09-02 | 2008-05-13 | Eastman Chemical Company | Optimized liquid-phase oxidation |
| US7608732B2 (en) * | 2005-03-08 | 2009-10-27 | Eastman Chemical Company | Optimized liquid-phase oxidation |
| US7495125B2 (en) * | 2004-09-02 | 2009-02-24 | Eastman Chemical Company | Optimized liquid-phase oxidation |
| US7582793B2 (en) * | 2004-09-02 | 2009-09-01 | Eastman Chemical Company | Optimized liquid-phase oxidation |
| US7692037B2 (en) * | 2004-09-02 | 2010-04-06 | Eastman Chemical Company | Optimized liquid-phase oxidation |
| US7568361B2 (en) * | 2004-09-02 | 2009-08-04 | Eastman Chemical Company | Optimized liquid-phase oxidation |
| US7507857B2 (en) * | 2004-09-02 | 2009-03-24 | Eastman Chemical Company | Optimized liquid-phase oxidation |
| US7390921B2 (en) * | 2004-09-02 | 2008-06-24 | Eastman Chemical Company | Optimized liquid-phase oxidation |
| US7563926B2 (en) * | 2004-09-02 | 2009-07-21 | Eastman Chemical Company | Optimized liquid-phase oxidation |
| DK2229956T3 (da) | 2004-09-13 | 2013-07-29 | Genzyme Corp | Multimere konstruktioner |
| WO2006042002A2 (en) * | 2004-10-05 | 2006-04-20 | Oregon Health And Science University | Compositions and methods for treating disease |
| US20090087424A1 (en) * | 2004-11-26 | 2009-04-02 | Noriko Miyamoto | Modulating Retinal Pigmented Epithelium Permeaion By Inhibiting Or Activating VEGFR-1 |
| US20060116531A1 (en) * | 2004-11-29 | 2006-06-01 | Wonders Alan G | Modeling of liquid-phase oxidation |
| US8211864B2 (en) * | 2005-01-26 | 2012-07-03 | Medical College Of Georgia Research Institute | Compositions and methods for the intracellular disruption of VEGF and VEGFR-2 by intraceptors |
| US7303748B2 (en) | 2005-02-02 | 2007-12-04 | Regeneron Pharmaceuticals, Inc. | Method of treating eye injury with local administration of a VEGF inhibitor |
| EP2447281B1 (en) | 2005-03-24 | 2015-12-16 | ThromboGenics N.V. | Novel anti-PLGF antibody |
| US20090170769A1 (en) * | 2005-05-13 | 2009-07-02 | Pei Jin | Cell surface receptor isoforms and methods of identifying and using the same |
| US7884232B2 (en) * | 2005-06-16 | 2011-02-08 | Eastman Chemical Company | Optimized liquid-phase oxidation |
| EP1904095B1 (en) | 2005-06-30 | 2013-05-29 | VIB, vzw | Treatment of liver cirrhosis and its complications |
| KR100737286B1 (ko) | 2005-08-31 | 2007-07-13 | 박기랑 | ＶＥＧＦＲ 트렁케이티드 ｃＤＮＡ를 함유하는 재조합아데노-연관 바이러스 및 이를 함유하는 암-특이적 유전자치료제 |
| US7355068B2 (en) | 2006-01-04 | 2008-04-08 | Eastman Chemical Company | Oxidation system with internal secondary reactor |
| US7358389B2 (en) * | 2006-01-04 | 2008-04-15 | Eastman Chemical Company | Oxidation system employing internal structure for enhanced hydrodynamics |
| US9073997B2 (en) * | 2007-02-02 | 2015-07-07 | Vegenics Pty Limited | Growth factor antagonists for organ transplant alloimmunity and arteriosclerosis |
| US7871100B2 (en) * | 2007-03-27 | 2011-01-18 | Wonderland Nurserygoods Co., Ltd. | Collapsible stroller |
| US20080260820A1 (en) * | 2007-04-19 | 2008-10-23 | Gilles Borrelly | Oral dosage formulations of protease-resistant polypeptides |
| CA2736929C (en) | 2008-10-02 | 2019-02-26 | Life Sciences Research Partners Vzw | Inhibition of plgf to treat philadelphia chromosome positive leukemia |
| PL2601214T3 (pl) | 2010-08-06 | 2018-05-30 | Genzyme Corporation | Kompozycje antagonistyczne wobec VEGF oraz ich zastosowania |
| JO3283B1 (ar) | 2011-04-26 | 2018-09-16 | Sanofi Sa | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) |
| ES2628321T3 (es) | 2011-12-01 | 2017-08-02 | Thrombogenics N.V. | Mejora del resultado de una trabeculectomía |
| TWI775096B (zh) | 2012-05-15 | 2022-08-21 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
| PT2956476T (pt) | 2013-02-18 | 2020-02-21 | Vegenics Pty Ltd | Moléculas de ligação e usos destas |
| US9914769B2 (en) | 2014-07-15 | 2018-03-13 | Kymab Limited | Precision medicine for cholesterol treatment |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| KR102537394B1 (ko) | 2014-03-17 | 2023-05-30 | 애드베룸 바이오테크놀로지스, 인코포레이티드 | 원추세포에서 증강된 유전자 발현을 위한 조성물 및 방법 |
| KR102486321B1 (ko) | 2014-07-18 | 2023-01-09 | 사노피 | 암을 앓고 있는 것으로 의심되는 환자를 아플리베르셉트로 치료한 결과를 예측하는 방법 |
| MY187898A (en) | 2015-03-02 | 2021-10-27 | Adverum Biotechnologies Inc | Compositions and methods for intravitreal delivery of polynucleotides to retinal cones |
| GB2545763A (en) | 2015-12-23 | 2017-06-28 | Adverum Biotechnologies Inc | Mutant viral capsid libraries and related systems and methods |
| KR102379464B1 (ko) | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
| EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| US20230372397A1 (en) | 2020-10-06 | 2023-11-23 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5240848A (en) | 1988-11-21 | 1993-08-31 | Monsanto Company | Dna sequences encoding human vascular permeability factor having 189 amino acids |
| US5332671A (en) | 1989-05-12 | 1994-07-26 | Genetech, Inc. | Production of vascular endothelial cell growth factor and DNA encoding same |
| US5194596A (en) * | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
| CN1701814A (zh) * | 1992-11-13 | 2005-11-30 | 马克斯普朗克科学促进协会 | 作为血管内皮生长因子受体的f1k－1 |
| AU684498B2 (en) * | 1993-03-25 | 1997-12-18 | Merck & Co., Inc. | Inhibitor of vascular endothelial cell growth factor |
| GB9410534D0 (en) * | 1994-05-26 | 1994-07-13 | Lynxvale Ltd | Improvements in or relating to growth factor inhibitors |
-
1997
- 1997-09-24 DE DE69736860T patent/DE69736860T2/de not_active Expired - Fee Related
- 1997-09-24 AU AU46503/97A patent/AU738806B2/en not_active Ceased
- 1997-09-24 EP EP97945258A patent/EP0928203B1/en not_active Expired - Lifetime
- 1997-09-24 CA CA002266419A patent/CA2266419A1/en not_active Abandoned
- 1997-09-24 WO PCT/US1997/017044 patent/WO1998013071A1/en not_active Ceased
- 1997-09-24 ES ES97945258T patent/ES2274549T3/es not_active Expired - Lifetime
- 1997-09-24 AT AT97945258T patent/ATE343400T1/de not_active IP Right Cessation
- 1997-09-24 JP JP10515840A patent/JP2001501471A/ja active Pending
-
1999
- 1999-10-26 US US09/427,353 patent/US6375929B1/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013516169A (ja) * | 2009-12-31 | 2013-05-13 | インダストリー−ユニバーシティー コーポレーション ファウンデーション ハンヤン ユニバーシティー | 抗血管新生活性を有する組換えアデノウイルス |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0928203A4 (en) | 2003-01-22 |
| EP0928203A1 (en) | 1999-07-14 |
| EP0928203B1 (en) | 2006-10-25 |
| AU4650397A (en) | 1998-04-17 |
| ES2274549T3 (es) | 2007-05-16 |
| CA2266419A1 (en) | 1998-04-02 |
| WO1998013071A1 (en) | 1998-04-02 |
| ATE343400T1 (de) | 2006-11-15 |
| AU738806B2 (en) | 2001-09-27 |
| US6375929B1 (en) | 2002-04-23 |
| DE69736860D1 (de) | 2006-12-07 |
| DE69736860T2 (de) | 2007-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2001501471A (ja) | 血管新生の阻害のための遺伝子治療 | |
| US8529905B2 (en) | Soluble inhibitors of vascular endothelial growth factor and use thereof | |
| US7731959B2 (en) | Antagonists of neuropilin receptor function and use thereof | |
| JPH10501423A (ja) | 遺伝子転移媒介の血管形成療法 | |
| JP2007195555A (ja) | 遺伝子発現を誘導するための組成物および方法 | |
| JP2001520875A (ja) | 血管新生の刺激のための遺伝子治療 | |
| EP1307582B1 (en) | Nucleic acid constructs, vascular cells transformed therewith, pharmaceutical compositions and methods utilizing same for inducing angiogenesis | |
| WO2002064023A2 (en) | Fra-1 expression in brain cancer | |
| JP2001503615A (ja) | Ｇａｘタンパク質の、転写の抑制に関与し、及び／又は他のタンパク質と相互作用する領域からなるポリペプチド、対応する核酸およびそれらの使用 | |
| WO2007089780A9 (en) | Bmx/etk tyrosine kinase gene therapy materials and methods | |
| WO2000064261A9 (en) | Role of vascular endothelial growth factor-b (vegf-b) in developing bones and uses thereof | |
| KR20090111776A (ko) | Ｍｓｘ1 단백질 또는 이를 코딩하는 유전자를 포함하는 종양의 혈관신생 저해제 | |
| MXPA00005516A (es) | Composiciones y metodos para inducir la expresion de genes | |
| WO2003006621A2 (en) | Super osteocalcin promoter for the treatment of calcified tumors and tissues | |
| JP2004504846A (ja) | 癌治療用ｐ９７２遺伝子をコードする発現ベクターおよびそれを生産するアデノウイルス | |
| JPWO2001098483A1 (ja) | 新規なｐｒｏｔｏｃａｄｈｅｒｉｎ様蛋白質をコードする遺伝子 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040921 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040921 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20061219 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070312 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070507 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070618 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20071016 |